Honigman Advises NeuroBo Pharmaceuticals in a Concurrent Private Placement and Registered Direct Offering of up to $70 Million

Honigman advised NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, on the sale of shares of common stock (or pre-funded warrants in lieu thereof) together with warrants to purchase shares of common stock in a private placement and a concurrent registered direct offering of shares of common stock. The private placement and the registered direct offering were priced at-the-market under Nasdaq rules.

The aggregate gross proceeds to NeuroBo from the offerings were approximately $20 million before deducting the placement agent’s fees and other offering expenses payable by NeuroBo. The potential additional gross proceeds to NeuroBo from the warrants, if fully exercised on a cash basis following approval by NeuroBo’s stockholders, will be approximately $50 million.

Read the transaction press release

The Honigman team was led by corporate partner Phillip D. Torrence, Joshua W. Damm, Samuel Katz and associate Garrett D. Packer. As part of Honigman’s Public Company, Securities and Corporate Governance Group, our team advises public companies in the life sciences space in complex offerings of securities and reporting and compliance matters.

About Honigman
Honigman LLP is an Am Law 200 full-service, general business law firm with more than 350 attorneys counseling clients on complex issues across the country in Chicago, Michigan (Ann Arbor, Bloomfield Hills, Detroit, Grand Rapids, Kalamazoo and Lansing), Washington, D.C. and in our newest wholly owned subsidiary office in Israel. Our lawyers counsel clients on complex issues in more than 60 areas of law. For more information, visit www.honigman.com.

# # #